Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EVAX Evaxion Biotech A/S

Trading 04-09 10:10:41 EDT

4.17

+0.11

+2.71%

High4.17	Low4.00	Vol2.37K
Open4.13	D1 Closing4.06	Amplitude4.18%
Mkt Cap34.62M	Tradable Cap23.07M	Total Shares8.30M
T/O9.58K	T/O Rate0.04%	Tradable Shares5.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EVAX","market":"US","secType":"STK","nameCN":"Evaxion Biotech A/S","latestPrice":4.17,"timestamp":1775743689958,"preClose":4.06,"halted":0,"volume":2367,"delay":0,"changeRate":0.027093596059113382,"floatShares":5531900,"shares":8302700,"eps":-1.202691,"marketStatus":"Trading","change":0.11,"latestTime":"04-09 10:10:41 EDT","open":4.13,"high":4.17,"low":4.0001,"amount":9578.7195021,"amplitude":0.041847,"askPrice":4.16,"askSize":80,"bidPrice":3.9,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.202691,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775764800000},"marketStatusCode":2,"adr":0,"adrRate":50,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":4.06,"preHourTrading":{"tag":"盘前","latestPrice":4,"preClose":4.06,"latestTime":"09:25 EDT","volume":13,"amount":52,"timestamp":1775741100062,"change":-0.06,"changeRate":-0.014778,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.06,"preClose":4.06,"latestTime":"17:54 EDT","volume":60,"amount":240.9695,"timestamp":1775685298574,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.618646,"impliedVol":2.1042,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/EVAX/wiki","defaultTab":"wiki","newsList":[{"id":"2625953971","title":"Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953971?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:55","pubTimestamp":1775566509,"startTime":"0","endTime":"0","summary":"Evaxion (EVAX) has completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-reports-last-patient-visit-in-one-year-extension-of-evx-01-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-reports-last-patient-visit-in-one-year-extension-of-evx-01-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","EVX","XBI","BK4585","BK4588","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930948","title":"Evaxion completes phase 2 EVX-01 trial extension; three-year data due H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930948","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930948?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:04","pubTimestamp":1775563493,"startTime":"0","endTime":"0","summary":"Evaxion completed one-year extension of phase 2 trial for personalized cancer vaccine EVX-01 in advanced melanoma, marking last patient’s final physician visit.Three-year clinical efficacy results will be presented in second half of 2026.Earlier one- and two-year results were already presented, showing broad and durable tumor response with no relapses reported at two-year follow-up.Third-year follow-up tested EVX-01 as monotherapy, supporting assessment of standalone activity versus prior combination use with Keytruda.Evaxion said EVX-01 remained well tolerated, reinforcing its AI-designed vaccine approach as it builds a longer-term efficacy package.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL9tKBDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500729","title":"European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500729","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624500729?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:09","pubTimestamp":1775142598,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.69% to 1,746.31 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and oil and gas company Eni , which climbed 4.5% and 4.1% respectively. They were followed by petroleum refiner Equinor  and telecommunications company Nokia , which advanced 2.8% and 2.2% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications  and lender Banco Santander , which dropped 6.5% and 3.5% respectively. They were followed by accommodations booking company trivago  and medical device maker EDAP TMS , which lost 2.4% each.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals , which soared 94%, followed by biopharmaceutical company Mereo BioPharma Group , which was up 3.1%. Oil and gas companies BP  and Shell  rose 1.9% and 1.8% respectively.The decliner","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LNOK","SHEH","DAVA","LU0072461881.USD","BPH","CUK","EDAP","SAN.AU","BK4547","BK4077","MREO","LU0084288595.USD","BK4207","LU0278409577.USD","LU0300736492.USD","LU0320765646.SGD","BK4007","BK4201","DAVA.AU","SAN","IE00BMPRXN33.USD","SHEL","SQNS","TRVG","E","EVAX","BK4082","BK4142","TRIB","BK4588","BK4141","AKTX","BK4107","LU0162691827.USD","NOK","BP","LU2236285917.USD","BK4117","BK4585","EQNR","AFG","BDRX","LU0300736062.USD","LU1162221912.USD","LU0098860793.USD","LU0648005311.SGD","BK4139","BK4020","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623953321","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2623953321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623953321?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:22","pubTimestamp":1774970573,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 1.72% to 1,721.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Cellectis , which climbed 7.6% and 4.4% respectively. They were followed by pharmaceutical company Ascendis Pharma  and biopharmaceutical company Grifols , which advanced 3.9% and 3.6% respectively.The only decliners from continental Europe were biotech firm Evaxion  and consumer goods company Unilever , which fell 5.8% and 5.5% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and pharmaceutical company Silence Therapeutics , which rose 10% and 6% respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group  and Bicycle Therapeutics , which were up 5.3% and 4.8% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech  and bioph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVAX","BK4117","GRFS","LU0109394709.USD","BK4588","BK4592","LU0124676726.USD","ASND","UL","CLLS","ULVR.UK","BK4585","DBVT","BK4505","BK4082","BK4139","BCYC","SNN","AUTL","AKTX","LU0889565916.HKD","BK4107","BK4007","BK4183","SLN","MREO","TRIB","LU0689626769.HKD","UN","LU0320765992.SGD","AFG","BDRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623775312","title":"Evaxion to present AI-designed next-generation polio vaccine concepts at World Vaccine Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2623775312","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623775312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:01","pubTimestamp":1774872112,"startTime":"0","endTime":"0","summary":"Evaxion will present AI-based next-generation polio vaccine design concepts at World Vaccine Congress in Washington, D.C., April 1, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLbZdJKN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621096131","title":"European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2621096131","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621096131?lang=en_us&edition=fundamental","pubTime":"2026-03-24 23:16","pubTimestamp":1774365369,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 0.31% to 1,701.97 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and telecommunications firm Nokia , which rose 2.1% and 2%, respectively. They were followed by petroleum refiner Equinor , which rose 1.2%.The decliners from continental Europe were led by biotech firm Evaxion  and software company SAP , which lost 4.6% and 4.4% respectively. They were followed by internet browser company Opera  and biopharmaceutical firm DBV Technologies , which fell 4.3% and 4.1% respectively.The gainers from the UK were led by oil and gas companies BP  and Shell , which advanced 2.1% and 1.5% respectively. They were followed by medical device maker Smith & Nephew  and biopharmaceutical company Amarin , which increased 1.4% and 1.2% respectively.The decliners from the UK and Ireland were led by Akari Therapeutics  and Biodexa P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHEH","IE00BMPRXR70.SGD","SHEL","OPRA","AFG","BK4117","SLN","BK4139","LU2236285917.USD","NOK","LU0300736492.USD","AMRN","BK4613","LU0072461881.USD","BK4007","BK4528","LU0300736062.USD","BK4020","BK4023","DAVA.AU","LNOK","EQNR","EVAX","BK4201","LU1829250122.USD","BK4107","BPH","EDAP","LU0648005311.SGD","DBVT","LU0162691827.USD","LU0084288595.USD","SAP","SNN","BK4134","IE00BMPRXN33.USD","LU0278409577.USD","LU1162221912.USD","LU0320765646.SGD","LU0098860793.USD","AKTX","BK4082","BDRX","BK4585","BK4588","DAVA","BP","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620263812","title":"Evaxion Calls April 16, 2026 AGM to Expand Capital and Warrant Authorizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2620263812","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620263812?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:31","pubTimestamp":1773927098,"startTime":"0","endTime":"0","summary":"Evaxion Biotech ( ($EVAX) ) has shared an announcement. Evaxion A/S has called its 2026 annual general meeting for April 16, 2026, in Hørsholm, Den...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-calls-april-16-2026-agm-to-expand-capital-and-warrant-authorizations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-calls-april-16-2026-agm-to-expand-capital-and-warrant-authorizations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4229","XBI","BK4585","BK4139","AGM","EVAX","BK4195","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620226842","title":"Evaxion Biotech Sets April 16, 2026 Date for Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226842","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226842?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:31","pubTimestamp":1773927065,"startTime":"0","endTime":"0","summary":"Evaxion Biotech ( ($EVAX) ) just unveiled an announcement. Evaxion A/S, a clinical-stage TechBio company listed on Nasdaq and headquartered in Denm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-biotech-sets-april-16-2026-date-for-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-biotech-sets-april-16-2026-date-for-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","XBI","BK4139","BK4588","BK4581","BK4585","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620223138","title":"Evaxion shareholders to vote on board authority for DKK 73.5 million convertible loan notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2620223138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620223138?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:01","pubTimestamp":1773925292,"startTime":"0","endTime":"0","summary":"Evaxion shareholders will vote on a board-backed proxy proposal to amend the articles to expand authorization to issue warrants to directors, executives and key employees up to DKK 11.9 million in nominal share value, without pre-emptive rights.The same proposal would authorize related share capital increases up to DKK 11.9 million to implement warrant exercises, with exercise prices set at market price.Shareholders will also vote on a board proposal to authorize issuance of convertible loan notes convertible into shares up to DKK 73.5 million in nominal share value, without pre-emptive rights, with conversion at or near market price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL7kL41n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225725","title":"Notice to convene Evaxion’s Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225725?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:00","pubTimestamp":1773925200,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, announces that its ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259026/0/en/Notice-to-convene-Evaxion-s-Annual-General-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4023","EVAX","AIYY","BK4139","BK4587","BK4588","BK4551","BK4528","AI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620946732","title":"Evaxion A/S Director Marianne Soegaard Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620946732","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620946732?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:10","pubTimestamp":1773882622,"startTime":"0","endTime":"0","summary":"Evaxion filed an initial statement of beneficial ownership on March 18, 2026, naming Marianne Soegaard as a director. The filing reported 3,361,687 ordinary shares held directly. It also reported 238,971 ordinary shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL43Rqsl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620943412","title":"Evaxion A/S files initial beneficial ownership statement for Chief AI Officer Andreas Holm Mattsson","url":"https://stock-news.laohu8.com/highlight/detail?id=2620943412","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620943412?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:09","pubTimestamp":1773882576,"startTime":"0","endTime":"0","summary":"Evaxion reported an initial statement of beneficial ownership for Andreas Holm Mattsson, its Chief AI Officer. The filing listed 1,382,395 ordinary shares held directly. It also reported 4,142,521 ordinary shares held indirectly through Mattsson Holding af 2008 ApS. The filing disclosed warrants exercisable for 645,700 ordinary shares at a conversion price of USD 0.059.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL2l8zMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620351294","title":"Evaxion A/S files Form 3 initial beneficial ownership statement for Chief Scientific Officer Birgitte Rono","url":"https://stock-news.laohu8.com/highlight/detail?id=2620351294","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620351294?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:08","pubTimestamp":1773882509,"startTime":"0","endTime":"0","summary":"Evaxion reported an initial statement of beneficial ownership for Birgitte Rono, Chief Scientific Officer, dated 03/18/2026. Rono reported direct ownership of 36,765 ordinary shares. Rono also reported warrants for 36,765 ordinary shares at an exercise price of USD 0.74. Rono reported additional warrants for 125,000 ordinary shares at an exercise price of USD 0.07.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8KZDrN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620294337","title":"Evaxion A/S Director Lars Holtug Files Initial Statement of Beneficial Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2620294337","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620294337?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:07","pubTimestamp":1773882465,"startTime":"0","endTime":"0","summary":"Evaxion reported an initial statement of beneficial ownership for director Lars Holtug dated March 18, 2026. The filing listed 258,029 ordinary shares beneficially owned indirectly. It also reported indirect warrants for 73,529 ordinary shares at an exercise price of USD 0.74. The filing reported indirect warrants for 92,250 ordinary shares at an exercise price of USD 0.06. It also listed direct warrants for 25,000 ordinary shares at an exercise price of USD 0.07.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL42s1Gn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620329433","title":"Evaxion A/S CEO Helen Katrina Tayton-Martin files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620329433","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620329433?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:06","pubTimestamp":1773882419,"startTime":"0","endTime":"0","summary":"Evaxion filed an initial statement of beneficial ownership naming Helen Katrina Tayton-Martin as chief executive officer. The filing reported 2,286,150 ordinary shares held indirectly. It also reported warrants for 2,500,000 ordinary shares at an exercise price of USD 0.12.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6cCzGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620405856","title":"Evaxion to Present New AI-Driven Cancer Vaccine Data at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405856","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405856?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:57","pubTimestamp":1773781047,"startTime":"0","endTime":"0","summary":"An update from Evaxion Biotech ( ($EVAX) ) is now available. Evaxion A/S, a Danish clinical-stage TechBio firm focused on AI-designed cancer and in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-to-present-new-ai-driven-cancer-vaccine-data-at-aacr-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-to-present-new-ai-driven-cancer-vaccine-data-at-aacr-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4585","BK4543","AI","XBI","BK4528","BK4139","BK4588","AIYY","BK4587","EVAX","BK4023","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620038244","title":"Evaxion to present two abstracts and attend AACR Oncology Industry Partnering event","url":"https://stock-news.laohu8.com/highlight/detail?id=2620038244","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620038244?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779440,"startTime":"0","endTime":"0","summary":"Evaxion will present two posters at the AACR Annual Meeting in San Diego on April 22, 2026, from 9am-12pm CST. One poster covers new biomarker and immunogenicity data for the personalized cancer vaccine EVX-01 in advanced melanoma. The second poster presents data on using the AI-Immunology platform to identify endogenous retrovirus-derived neoantigens for a personalized glioblastoma vaccine strategy. Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meeting.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2knPl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4112","LU0314104364.USD","LU2095319765.USD","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014021.USD","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","BK4139","EVAX","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619462654","title":"European Equities Traded in the US as American Depositary Receipts Higher Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2619462654","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619462654?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:22","pubTimestamp":1773674559,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Monday morning, up 1.7% to 1,741.84 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by solar energy technology company Turbo Energy  and clinical stage biotechnology company Abivax , which rose 7.5% and 5.7% respectively. They were followed by telecommunications and consumer electronics company Nokia , which added 4.3%.The decliners from continental Europe were led by biotech company Evaxion  and construction engineering company Cadeler , which fell 7.3% and 4% respectively. They were followed by clinical stage biopharmaceutical company DBV Technologies , which was down 0.8%.From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics  and cruise line operator Carnival , which rose 5.9% and 3.8% respectively.The decliners from the UK and Ireland were led by oncology biotech company Akari Therapeutics  and clinical stage biotech company Biode","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DBVT","AKTX","BK4007","AFG","BK4142","ABVX","BK4139","BK4096","LNOK","BK4117","NOK","CUK","SLN","BDRX","IE00BMPRXN33.USD","TURB","IE00BMPRXR70.SGD","BK4107","CDLR","BK4547","BK4020","BK4129","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619711926","title":"European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2619711926","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619711926?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:11","pubTimestamp":1773418305,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.29% to 1,721.83 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and biopharmaceutical company Cellectis , which rose 8.3% and 7.8% respectively. They were followed by telecommunications Nokia  and medical device maker EDAP , which increased 3.6% and 2.9% respectively.The decliners from continental Europe were led by 3D printer company Materialise  and accommodations booking site trivago , which fell 2.2% and 2% respectively. They were followed by lender ING   biopharmaceutical company Grifols , which were down 1.8% and 1.7% respectively.The gainers from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group  and cruise line operator Carnival , which advanced 3.2% and 1.1% respectively. They were followed by telecommunications operator Vodafone  and alcoholic beverage company Diageo , which were u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0300736062.USD","BK7505","BK4117","BCYC","BK4168","AFG","EVAX","BK4132","BK4023","BK4559","BK4142","BK7507","BK4588","BK4139","IE00BMPRXR70.SGD","BK4020","GRFS","BHP.AU","VOD","ING","BK4505","BK4585","BK7141","BK4547","IE00BMPRXN33.USD","BK4007","ING.AU","BK7511","CLLS","TRVG","BK4546","AKTX","DEO","BK7095","BDRX","BK4082","DGE.UK","MREO","LU0300736492.USD","CUK","EDAP","BK4077","BK4207","LNOK","NOK","BK4169","MTLS","BK4532","BHP","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618588301","title":"European Equities Traded in US as ADRs Slump in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2618588301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618588301?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:10","pubTimestamp":1773328202,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts slumped late Thursday morning with the S&P Europe Select ADR Index declining 1.9% to 1,723.21.From continental Europe, the gainers were led by biotech firm Evaxion  and telecommunications company Nokia , which climbed 6.4% and 3.5%, respectively. They were followed by 3D printer company Materialise  and petroleum refiner Equinor , which advanced 3.4% and 2.3%, respectively.The decliners from continental Europe were led by lender Banco Bilbao Vizcaya Argentaria  and biopharmaceutical company Cellectis , which dropped 6% and 5.5%, respectively. They were followed by lenders Banco Santander  and ING , which lost 4.1% and 3.9%, respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics  and oil and gas company BP , which rose 1.9% and 1.3%, respectively. They were followed by utility company National Grid  and oil and gas company Shell , which were up 1.2% and 1.1%, respective","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","IE00BMPRXR70.SGD","CLLS","BCS","BK4020","SHEL","LU0072461881.USD","LNOK","LU0310800965.SGD","LU1267930227.SGD","BK4208","BK4007","HSBC","AKTX","BK4207","HSBH","BK4532","LU0320765646.SGD","ING.AU","LU2236285917.USD","LU0300736492.USD","MTLS","BK4588","EVAX","SHEH","BPH","BK4547","LU0128525689.USD","LU0278409577.USD","SAN","NGG","ING","BBVA","SAN.AU","BP","EQNR","LU0300736062.USD","NOK","LU1829250122.USD","BK4521","BK7142","BK4546","CUK","AUTL","BK4023","LU0098860793.USD","BK7141","BK7505","BK4142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evaxion.ai","stockEarnings":[{"period":"1week","weight":0.0305},{"period":"1month","weight":0.3182},{"period":"3month","weight":-0.2055},{"period":"6month","weight":-0.3119},{"period":"1year","weight":1.942},{"period":"ytd","weight":-0.1488}],"compareEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0033},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.0352},{"period":"1year","weight":0.3616},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.312391},{"month":2,"riseRate":0,"avgChangeRate":-0.075072},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.067423},{"month":4,"riseRate":0.666667,"avgChangeRate":0.078193},{"month":5,"riseRate":0.4,"avgChangeRate":0.067918},{"month":6,"riseRate":0.2,"avgChangeRate":-0.044814},{"month":7,"riseRate":0.4,"avgChangeRate":0.060856},{"month":8,"riseRate":0.6,"avgChangeRate":-0.04913},{"month":9,"riseRate":1,"avgChangeRate":0.19717},{"month":10,"riseRate":0.4,"avgChangeRate":0.102065},{"month":11,"riseRate":0.2,"avgChangeRate":-0.236379},{"month":12,"riseRate":0,"avgChangeRate":-0.21322}],"exchange":"NASDAQ","name":"Evaxion Biotech A/S","nameEN":"Evaxion Biotech A/S","securityTypeName":"DR","adrRate":"1:50"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evaxion Biotech A/S,EVAX,Evaxion Biotech A/S股票,Evaxion Biotech A/S股票老虎,Evaxion Biotech A/S股票老虎国际,Evaxion Biotech A/S行情,Evaxion Biotech A/S股票行情,Evaxion Biotech A/S股价,Evaxion Biotech A/S股市,Evaxion Biotech A/S股票价格,Evaxion Biotech A/S股票交易,Evaxion Biotech A/S股票购买,Evaxion Biotech A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction